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Accurate assessment of systemic iron status in cystic ﬁbrosis will avoid the
hazards of inappropriate iron supplementationDear Editor,
We read with interest the report by Hoo and Wildman [1],
which illustrates the potential for adverse events with parenteral
iron infusion in “iron deficient” patients with cystic fibrosis
(CF) resistant to oral iron supplementation. The authors rightly
highlight the role that iron plays in Pseudomonas aeruginosa
infection in CF. Abnormal airway iron levels in CF were first
described by Stites et al. and our group subsequently confirmed
this followed by the demonstration of a positive relationship
between sputum iron levels and quantitative load ofP. aeruginosa
[2,3]. Iron probably has a pivotal role in P. aeruginosa infection
in CF and our data also suggest that P. aeruginosa isolates from
CF patients will not form biofilms under low oxygen conditions
without the availability of iron [4]. Whilst these observations
open the door to potential therapeutic interventions targeting iron,
there remains the unanswered question of the optimal route of
delivery.
The role of iron in facilitating P. aeruginosa infection
questions the rationale for iron supplements (whether oral or
systemic) in CF. Conventional measures used to assess iron status
in patients with CF are frequently abnormal, but this predomi-
nantly reflects the iron withholding response of the body to
inflammation and infection. Therapeutically negating this ancient
eukaryote response to bacterial pathogens by administering iron
directly into the systemic circulation may lead to deleterious
effects, as the authors have discovered. Whether the clinical
worsening in the patients reported by Hoo and Wildman and the
subsequent increase in inflammatory markers was a result of
enhanced bacterial replication or potentially, iron generated
oxidative stress and tissue injury (systemically or within the lung)
is unknown, but both explanations are biologically possible.
The authors do not present data on systemic iron status, but the
diagnosis of “true” iron deficiency in the setting of inflammation
can be difficult. We have shown that the use of traditional
measures of iron status to screen for iron deficiency in the CF
population result in high false positive rates (up to 75%) and also
misses some cases of iron deficiency (unpublished data). The best
non-invasive test of “true” iron deficiency is the soluble transferrin
receptor (sTfR) to log ferritin ratio (sTfR ratio) [5]. This method1569-1993/$ -see front matter. Crown Copyright © 2012 Published by Elsevier B.V
http://dx.doi.org/10.1016/j.jcf.2012.10.001should become the standard for systemic iron assessment in CF to
prevent injudicious administration of iron supplementation andwe
now use it to guide parenteral iron supplementation in all patients.
When intravenous iron has been appropriately administered in
patients who are truly iron deficient (ferritinb12 mg/l or sTfR
ratioN2), despite oral supplementation, we have not observed
increased systemic inflammation in our CF cohort, in contrast to
the author's findings.
However, in an earlier audit of the outcomes of iron infusions
in patients with CF from our Centre we have observed high rates
of allergic phenomenon including anaphylaxis adding to the need
for great caution in the administration of all forms of intravenous
iron. We speculate that this high complication rate maybe the
result of heightened systemic inflammation in this patient group.
For this reason, we support Hoo and Wildman's recommenda-
tions that iron infusions be administered towards the end of an
antibiotic course and with continued antibiotic cover and close
patient monitoring in case of adverse events.
Future, prospective studies in this area should ensure that
iron deficiency is carefully defined in CF patients and assess
the impact that systemic iron administration has upon airway
infection, airway iron levels and oxidative stress, and relate
these to clinical outcomes.References
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